MBMavis Boakye-Yiadom

Mavis Boakye-Yiadom

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mavis Boakye-Yiadom has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bridelia ferruginea Tea Consumption Improves Antioxidant Status in Individuals Living with Type 2 Diabetes

    by Collins Afriyie Appiah, Jennifer Ngounda, Mavis Boakye-Yiadom, Felix Charles Mills-Robertson, Mariette Nel, Rabia Johnson, Corinna Walsh

    Background: It is well-known that persistent hyperglycaemia predisposes individuals with diabetes to oxidative stress. Bridelia ferruginea Benth., a tropical African plant, is known for its antioxidant activity. Methods: This comparative cross-sectional study assessed the oxidative status and associated parameters in 70 individuals living with type 2 diabetes (ILWT2D) who were receiving standard diabetes treatment and consistently drank Bridelia tea (Bridelia group) compared to 92 ILWT2D receiving standard diabetes treatment only (comparator group). Lipid peroxidation assessed using thiobarbituric acid reactive substances (TBARS) served as an indicator of oxidative stress. In addition, the total antioxidant capacity (TAC), glycated haemoglobin (HbA1c), and dietary intake of antioxidant-rich foods were assessed. Results: The comparator group had significantly better glycaemic control [median HbA1c—7.7% (IQR 6.7–9.4)] than the Bridelia group [9.2% (7.6–11.4)], p = 0.001. The comparator group had been on metformin treatment for a significantly longer period than the Bridelia group (p < 0.0001). Participants in the comparator group consumed antioxidant-rich fruits more frequently (monthly basis) than those in the Bridelia group who ate fruits seldomly (p < 0.0001). There was no significant difference (p = 0.11) observed in oxidative stress levels between the Bridelia group and the comparator group [TBARS: 323.0 ng/L (287.5–374.0) and 317.0 ng/L (272.5–342.0), respectively]. Nonetheless, the Bridelia group had significantly higher antioxidant capacity (p = 0.001) compared to the comparator group [TAC: 1.01 mmol/L (0.93–1.10) versus 0.92 mmol/L (0.84–1.03), respectively]. Participants in the comparator group, who did not drink Bridelia tea, had been on longer metformin treatment with better glycaemic control. However, those who drank the Bridelia tea showed comparable levels of oxidative stress and exhibited elevated antioxidant levels compared to those who did not. Conclusions: Bridelia tea consumption may serve as a sustainable source of antioxidants; however, its effect on mitigating oxidative stress in ILWT2D requires further investigation, particularly given that no significant improvement in TBARS was observed. Future studies are needed to clarify the potential role of Bridelia tea in oxidative stress management in resource-limited settings like Ghana.


  • Open Access

    The use of Nibima and Immunim , two Ghanaian herbal medicines in the management of mild COVID‐19: A case report

    by Mavis Boakye‐Yiadom, Ronald Yeboah, David Offei‐Abrokwa, Ekuwa Baisiwa Wilson, Samuel Annang Darko, Emmanuel Tamakloe

    Key Clinical Message: Nibima and Immunim manages mild COVID‐19 in 7 days. Coronavirus Disease 2019 (COVID‐19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) can lead to severe complications and deaths. The search for phytotherapeutic agents to augment the fight against the current COVID‐19 pandemic is therefore of highest priority. A 52‐year‐old female with no history of chronic illness presented to our clinic facility with a 3 days loss of smell and headache which persisted after self‐medication. The patient tested positive for COVID‐19 in the SARS‐CoV‐2 Ag test as well as the Typhoid rapid antibody test. Routine laboratory tests were not remarkable. A 60 mL three times daily dose of Nibima and 5 mL in 40 mL of warm water dose of Immunim were given to the patient for 7 days. Patient recovered sense of smell and regained appetite but cough although reduced persisted. She also tested negative for COVID‐19 after 7 days treatment. This case is the first documented case of COVID‐19 management with herbal medicines in Ghana. We strongly suggest a larger control trial on these products to ascertain these findings to repurpose them as viable treatments for COVID‐19.


  • Open Access

    A review on anti-peptic ulcer activities of medicinal plants used in the formulation of Enterica, Dyspepsia and NPK 500 capsules

    by Doris Kumadoh, Mary-Ann Archer, Genevieve N. Yeboah, Michael O. Kyene, Mavis Boakye-Yiadom, Ofosua Adi-Dako, Christina Osei-Asare, Emmanuel Adase, Alfred A. Appiah, Susana O. Mintah


  • Open Access

    Medicinal Plants with Prospective Benefits in the Management of Peptic Ulcer Diseases in Ghana

    by Mavis Boakye-Yiadom, Doris Kumadoh, Emmanuel Adase, Eric Woode

    Background. The growth or multiplication of harmful microorganisms in addition to harmful human activities has led to many disorders in humans. Consequently, there is a search for medications to treat these disorders. Interestingly, medicines of plant origin are known to be among the most attractive sources of new drugs and have shown promising results in the treatment of various diseases including peptic ulcers. This review, therefore, is aimed at obtaining knowledge on some Ghanaian ethnomedicinal plants used to treat peptic ulcers, their folkloric uses, their phytochemicals, and their antiulcer and related pharmacological activities as well as finding areas for prospective studies.Methods. Published peer‐reviewed articles on ethnomedicinal plants used for the management of peptic ulcers in Ghana from 1967 to 2020 were sourced and used for the study. Results. In this review, 13 plants were identified which belong to 10 different families including Sapindaceae, Apocynaceae, and Bignoniaceae. The parts most often used for most preparations were the leaves (53%), followed by stem bark and roots (both having the same percentage of use of 17.6%), the whole plant (5.9%), and the rhizomes (5.9%). Azadirachta indica was the only plant that had undergone some patient studies in addition to animal studies. Conclusion. A discussion of various antiulcer activity studies using ulcer models carried out on selected medicinal plants used for the management of peptic ulcer disease in addition to brief information on their folkloric uses and their phytochemical and other pharmacological properties is presented. These medicinal plants may be used in developing herbal products for the management of peptic ulcer disease.


  • Open Access

    Safety and Effectiveness of Mist Antiaris, a Herbal Preparation for Treatment of Peripheral Neuropathy

    by S. Antwi, J. Asiedu-Larbi, O. N. K. Martey, O. Quasie, M. Boakye-Yiadom, F. Ayertey, R. Yeboah, C. A. Sapaty, D. Offei-Abrokwa, D. Oduro-Mensah, et al.

    Mist Antiaris is a herbal decoction for treatment of nervous disorders. Safety and efficacy were evaluated in Sprague-Dawley rats and human patients, respectively. Acute toxicity was assessed by administration of a single 5000 mg/kg oral dose of decoction to a group of six rats. For subchronic toxicity, four groups of six rats each received water (control) or 10, 100, or 200 mg/kg oral doses of decoction daily for eight weeks. Body weight, serum, urine, and hematological profile of the animals in each group were monitored over the period. Effects of treatment on pentobarbital-induced sleeping time and histology of liver, lung, heart, and kidney tissue were assessed at the end of the study. There was no evidence of acute toxicity within 48 hours of the oral dose. Over the 8-week period, body weight increases in Mist Antiaris treatment groups were reduced relative to the control group. There were no significant differences in urine profile, serum biochemistry, hematological parameters, and pentobarbital-induced sleeping time. Tissue histology revealed no differences relative to controls. Assessment of efficacy was by retrospective review of data on patients who presented with peripheral neuropathy. Treatment resulted in 53.7 % of patients reporting complete resolution and 15.7 % showing reduction in neuropathic symptoms. The data demonstrate that there is no toxicity due to subchronic administration of Mist Antiaris in Sprague-Dawley rats. The reduction or resolution of neuropathic symptoms indicated by patents’ file data provides evidence to suggest that Mist Antiaris has antineuropathic effects.